Overview

Bisoprolol in Hypertension: Effect on Concomitant Elevated Heart Rate

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
0
Participant gender:
All
Summary
The b.p.m study will be performed to gain the insight in the courses of illness and therapy in subjects, suffering from hypertension and that have elevated heart rate. This study will show that a therapy with bisoprolol (Concor/Concor PLUS) or any other blood pressure lowering (antihypertensive) drug lowers blood pressure (BP) and heart rate and increases the quality of subjects' life.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Collaborator:
Merck Gesellschaft mbH, Austria
Treatments:
Bisoprolol
Criteria
Inclusion Criteria:

- Subjects with high blood pressure (BP) and tachycardia

- Subjects with essential hypotonia, angina pectoris

- Subjects with essential hypertonia, when a therapy with ß-blockers or diuretics is not
sufficiently effective

- Precautions to be taken in case of severe peripheral circulation disorders, diabetes
(especially at the time, when blood sugar is elevated), during a strict fast, in case
of metabolic acidosis, atrioventricular block (AV) block of grade I, Prinzmetal
angina, additional therapy with angiotensin-converting enzyme inhibitors
(ACE-inhibitors), severe coronary or cerebral sclerosis, hyperuricemia or gout and in
subjects with a history of severe hypersensitive reactions or during a desensitization
therapy (excessive anaphylactic reaction, attenuated adrenergic counterregulation)

- Special precautions must be taken with the subjects that have a family history or
suffered from psoriasis, during a desensitization therapy (also anamnestic subjects),
other obstructive pulmonary diseases on account of the possibility of initiation or
intensification of bronchoconstriction, although, due to the marked ß1-selectivity of
bisoprolol, the risk is lower than with non-selective ß-receptor blockers. The
subjects that have a family history or suffered from psoriasis should the take Concor
Plus only after a careful assessment of risk - benefit ratio. The subjects with
pheochromocytoma should take Concor Plus, as well as other ß-blockers after inhibiting
the alpha-receptors

Exclusion Criteria:

- Subjects with acute cardiac insufficiency, sinus sick syndrome, bradycardia and
anaemia

- Contraindicated medical conditions for bisoprolol as defined in the Product
Information, i.e. a known hypersensitivity to the active agent bisoprolol or one of
the inactive ingredients of the medication; acute heart failure or decompensation of
heart insufficiency, that requires a therapy with inotropic agents; cardiogenic shock;
AV block grade II or III (in the absence of cardiac pacemakers); sick sinus syndrome,
sinoatrial heart block; symptomatic bradycardia; symptomatic hypotonia; severe asthma
bronchiolus or severe chronic obstructive airways disease; advanced stages of
peripheral arterial disease or Raynaud's Syndrome; untreated pheochromocytoma,
metabolic acidosis

- Contraindicated medical conditions for bisoprolol + hydrochlorothiazide (HCTZ) as
defined in the Product Information, i.e. hypersensitivity to the ingredients of the
medication containing bisoprolol + HCTZ, uncompensated heart insufficiency, pulmonary
hypertension, cardiogenic shock, AV block, grades II and III. sick sinus syndrome (in
the absence of cardiac pacemakers), sinoatrial heart block, severe bradycardia with
less than 50 beats/min from the start of treatment, hypotension(systolic less than 90
mmHg), acute asthmatic attack, intravenous administration of calcium antagonists of
Verapamil type, simultaneous treatment with monoamine oxidase inhibitors
(MAO-inhibitors), advanced stages of peripheral circulation disorder, severe
therapy-resistant potassium deficiency, severe hyponatraemia, hypercalcaemia, severe
renal dysfunction (serum creatinin over 1.8 mg/100 ml and/or creatinin clearance under
30 ml/min); acute glomerulonephritis; liver coma; children, not previously treated;
pregnancy and breastfeeding